MainStreet Investment Advisors LLC Acquires New Holdings in Thermo Fisher Scientific Inc. $TMO

MainStreet Investment Advisors LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,336 shares of the medical research company’s stock, valued at approximately $1,353,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Flossbach Von Storch SE raised its holdings in Thermo Fisher Scientific by 93.0% in the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after buying an additional 1,314,182 shares during the last quarter. Nuveen LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $532,360,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Thermo Fisher Scientific by 29.5% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,257,424 shares of the medical research company’s stock worth $915,295,000 after buying an additional 514,399 shares during the period. EdgePoint Investment Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $172,139,000. Finally, Lindsell Train Ltd grew its holdings in Thermo Fisher Scientific by 68.0% in the second quarter. Lindsell Train Ltd now owns 854,612 shares of the medical research company’s stock worth $346,511,000 after purchasing an additional 345,822 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. TD Cowen increased their price target on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Robert W. Baird raised their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research note on Thursday, July 24th. Cowen reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Barclays boosted their target price on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Finally, Argus raised their price objective on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Nineteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $601.65.

Thermo Fisher Scientific Stock Down 1.9%

TMO stock opened at $567.49 on Tuesday. The company’s 50 day moving average is $529.51 and its 200 day moving average is $469.36. The stock has a market cap of $213.21 billion, a price-to-earnings ratio of 32.78, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Thermo Fisher Scientific announced that its board has approved a share buyback plan on Thursday, November 6th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 17,104 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $65,247,057.48. This trade represents a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Lisa P. Britt sold 10,225 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the sale, the vice president directly owned 14,145 shares of the company’s stock, valued at $8,085,564.90. This trade represents a 41.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 52,140 shares of company stock valued at $29,104,464. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.